DSMB case study: Decision making when a similar clinical trial is stopped early

David W. Hillman; Thomas A. Louis

doi:10.1016/S0197-2456(02)00274-X

DSMB case study: Decision making when a similar clinical trial is stopped early

David W. Hillman, Thomas A. Louis

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

Two similarly designed, placebo-controlled clinical trials are fully accrued and following patients for safety and outcome data. One trial is stopped at a planned interim analysis by its data safety and monitoring board (DSMB) due to a statistically significant treatment benefit. The statisticians and DSMB of the other trial are informed of these results. What are the responsibilities of the statistical center? How should the DSMB deal with the situation if the data do not support the stopped trial? What should the patients be told concerning the results of the two trials when one trial continues and the other is stopped? This DSMB case study reports on such a situation for two randomized clinical trials of oral ganciclovir for the prevention of cytomegalovirus disease in HIV/AIDS patients.

Original language	English (US)
Pages (from-to)	85-91
Number of pages	7
Journal	Controlled clinical trials
Volume	24
Issue number	1
DOIs	https://doi.org/10.1016/S0197-2456(02)00274-X
State	Published - Feb 1 2003

Keywords

Clinical trial
Data and Safety Monitoring Board (DSMB)
Interim monitoring

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/S0197-2456(02)00274-X

Fingerprint Dive into the research topics of 'DSMB case study: Decision making when a similar clinical trial is stopped early'. Together they form a unique fingerprint.

Cite this

@article{536c1ee31b074a749bf31d7834f7a135,

title = "DSMB case study: Decision making when a similar clinical trial is stopped early",

abstract = "Two similarly designed, placebo-controlled clinical trials are fully accrued and following patients for safety and outcome data. One trial is stopped at a planned interim analysis by its data safety and monitoring board (DSMB) due to a statistically significant treatment benefit. The statisticians and DSMB of the other trial are informed of these results. What are the responsibilities of the statistical center? How should the DSMB deal with the situation if the data do not support the stopped trial? What should the patients be told concerning the results of the two trials when one trial continues and the other is stopped? This DSMB case study reports on such a situation for two randomized clinical trials of oral ganciclovir for the prevention of cytomegalovirus disease in HIV/AIDS patients.",

keywords = "Clinical trial, Data and Safety Monitoring Board (DSMB), Interim monitoring",

author = "Hillman, {David W.} and Louis, {Thomas A.}",

year = "2003",

month = feb,

day = "1",

doi = "10.1016/S0197-2456(02)00274-X",

language = "English (US)",

volume = "24",

pages = "85--91",

journal = "Controlled Clinical Trials",

issn = "0197-2456",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - DSMB case study

T2 - Decision making when a similar clinical trial is stopped early

AU - Hillman, David W.

AU - Louis, Thomas A.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Two similarly designed, placebo-controlled clinical trials are fully accrued and following patients for safety and outcome data. One trial is stopped at a planned interim analysis by its data safety and monitoring board (DSMB) due to a statistically significant treatment benefit. The statisticians and DSMB of the other trial are informed of these results. What are the responsibilities of the statistical center? How should the DSMB deal with the situation if the data do not support the stopped trial? What should the patients be told concerning the results of the two trials when one trial continues and the other is stopped? This DSMB case study reports on such a situation for two randomized clinical trials of oral ganciclovir for the prevention of cytomegalovirus disease in HIV/AIDS patients.

AB - Two similarly designed, placebo-controlled clinical trials are fully accrued and following patients for safety and outcome data. One trial is stopped at a planned interim analysis by its data safety and monitoring board (DSMB) due to a statistically significant treatment benefit. The statisticians and DSMB of the other trial are informed of these results. What are the responsibilities of the statistical center? How should the DSMB deal with the situation if the data do not support the stopped trial? What should the patients be told concerning the results of the two trials when one trial continues and the other is stopped? This DSMB case study reports on such a situation for two randomized clinical trials of oral ganciclovir for the prevention of cytomegalovirus disease in HIV/AIDS patients.

KW - Clinical trial

KW - Data and Safety Monitoring Board (DSMB)

KW - Interim monitoring

UR - http://www.scopus.com/inward/record.url?scp=0037307422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037307422&partnerID=8YFLogxK

U2 - 10.1016/S0197-2456(02)00274-X

DO - 10.1016/S0197-2456(02)00274-X

M3 - Article

C2 - 12559646

AN - SCOPUS:0037307422

VL - 24

SP - 85

EP - 91

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 1

ER -